Phoenix, Arizona--(Newsfile Corp. - May 17, 2021) - The Stock Day Podcast welcomed GenBio, Inc. and Dakshidin Corp (OTC Pink: DKSC) ("the Company"). Giles Tilley, Managing Director of GenBio Inc. an early-stage Biotechnology Company with unrivaled (and possibly unique) research expertise based on an unexpected yet vitally important medical research breakthrough - described by the US scientific team as "never seen before", and Dakshidin Corp. CEO, Chris Haigh, joined Stock Day host Everett Jolly.
"How did you get involved with GenBio?", Jolly asked Haigh. "It was prior to the epidemic to start with," explained Haigh. "I was introduced to Giles by a mutual acquaintance who thought that there was a synergy between us," he continued, noting that Dakshidin is in the process of being renamed 'Whitechapel Holdings'. "Whitechapel is very involved, and has been for a long time, in the health and wellness space, but completely organic and natural," said Haigh.
"We've looked at a number of different approaches to what we felt, based upon market research, were the significant issues and complaints where products should be designed and aimed at," continued Haigh. "Giles is an absolute authority on natural products, the science behind them, and how to be able to refine the extracts from those products," he shared. "When Giles and I first met it became obvious to both of us that there was a tremendous synergy there."
"Who is GenBio and what is your mission?", Jolly asked Tilley. "We are primarily a US-based biotech research company and our mission is to develop the next generation of anti-inflammatory drugs," said Tilley. "In Australia, there are natural extracts that demonstrate outstanding potential in the medical and health field," he added, noting that GenBio has studied around 300 extracts over the last five years. "We have whittled it down to about five, which we believe merit research," continued Tilley. "Out of those five, probably two or three are undergoing research in the USA," he shared. "We have identified new mechanisms of action, which gives us leverage in the marketplace."
Tilley then shared that these extracts also have the potential to be added to CBD formulations. "In so doing, one of two things can happen; you either have an additive effect or in certain cases we can design them with a synergistic effect to make them much more helpful and powerful," said Tilley.
"What is your company's unique selling point?", asked Jolly. "The unique selling point of our company is that we currently have a research program with an entirely new mechanism of action, an entirely new platform, and a more powerful anti-inflammatory drug program with, we believe, lower toxicity than existing pharmaceutical drugs," shared Tilley. "That is about to enter an Investigational New Drug program in the United States, as we speak."
Jolly then asked about the potential of the synergy between these two companies. "The health and wellness space, following the pandemic, is now a much larger space where customers are much more interested in their personal health, as well as the education behind that," said Haigh. "Having the science supplied by GenBio and having unique products that are aimed specifically at these viral issues, we believe, will give us the edge in that market."
"You believe this is going to dovetail into your company's sales and operations, and will hit your bottom line in the next two to four quarters?", asked Jolly. "Significantly," responded Haigh.
To close the interview, Tilley and Haigh expressed confidence in the potential of their partnership to develop the next generation of anti-inflammatory drugs as the health and wellness industry continues to transform. "What we hope for is a line of absolutely organic and natural products that are effective and will truly help with health issues without the use of pharmaceuticals," closed Haigh.
To hear the entire interview with Giles Tilley and Chris Haigh, follow the link to the podcast here: https://audioboom.com/posts/7866978-genbio-inc-discusses-entering-the-191-billion-dollar-anti-inflammatory-market-potential-of-the.
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.
GenBio Inc. is an early-stage Biotechnology Company with unrivaled (and possibly unique) research expertise based on an unexpected yet vitally important medical research breakthrough - described by the US scientific team as "never seen before".
Company Contact Information
Investor Relations
Telephone number:
(949) 716-6030
Emails:
General inquiries: genbioinc@gmail.com
Investor Inquiries: trilogyir@gmail.com
Company Website, Social Media Outlets, and Crowdfunding Opportunity
GenBio Inc. , Twitter, Facebook, LinkedIn
About Dakshidin Corporation (OTC Pink: DKSC) and Whitechapel Holdings
DKSC has positioned itself as an innovator and industry leader in the quickly emerging organic health and wellness industry.
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
SOURCE:
Stock Day Media
(602) 821-1102
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84293
